Bristol-Myers Squibb shares gained after the company announced that it will enroll additional patients in the ADEPT-2 study.
Hosted on MSN
Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer
We recently published 8 Stocks That Jim Cramer Recently Talked About. Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently discussed. Bristol-Myers Squibb Company (NYSE:BMY ...
On the surface, outside circumstances don't appear favorable for pharmaceutical giant Bristol-Myers Squibb Co (NYSE:BMY), which finds itself caught in a political wake. Earlier this week, President ...
Bristol-Myers Squibb & Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, ...
Bristol-Myers Squibb (NYSE:BMY) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are ...
Christopher Boerner, CEO & Chairman, highlighted, "Q3 was another strong quarter, reflecting focused execution across the business as we continue to make progress on our plan to position Bristol-Myers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback